ClinicalTrials.gg
Active, not recruitingNCT05307705PIKASSO-01Updated Oct 14, 2026

A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors

A Phase 1 interventional study of LOXO-783 and Fulvestrant in Breast Cancer, sponsored by Eli Lilly and Company. Active, not recruiting at 50 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment

How we know · 14 judgments

Updated Oct 14, 2026Now Active, not recruitingPrimary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
260
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 88 studies in Breast Neoplasms by Eli Lilly and Company — 7 open to participants now, 22 under way, 8 of them phase 3. Breast Neoplasms · Eli Lilly and Company.

Planned enrollment
21st of 80
260 · median 138
Started
2022
with 3 others
Phase 1
17 of 88
3 open now
Primary completion
2025-04
later than 13 of 21 live
Registered
79th of 88
by date

Among the 88 studies in Breast Neoplasms by Eli Lilly and Company, this one is the 21st largest by planned enrollment of the 80 interventional ones that give a count, is one of 4 that started in 2022, is one of 17 in phase 1, reaches primary completion later than 13 of the 21 other live ones, and was the 79th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

7 of the 88 studies in Breast Neoplasms by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 88 studies in Breast Neoplasms by Eli Lilly and Company, or all of them as a file.
02

Study summary

The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-783. LOXO-783 may be used to treat breast cancer and other solid tumors that have a change in a particular gene (known as the PIK3CA gene). Participation could last up to 36 months (3 years) and possibly longer if the disease does not get worse.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have advanced breast cancer or another solid tumor with the presence of a phosphatidylinositol 3-kinase catalytic subunit alpha (PIK3CA) H1047R mutation (or other Sponsor and safety review committee (SRC)-approved, activating PIK3CA mutations other than H1047R mutation)
  • Have adequate sample available or be approved by the Sponsor for enrollment if no tumor sample is available.
  • Have stopped all cancer treatment and have recovered from the major side effects
  • Have adequate organ function, as measured by blood tests
  • Have a performance status of 0 or 1 on the (ECOG) scale
  • Patients must have

    • --- Patients with non-breast tumor types must have at least 1 measurable lesion

    • Non-measurable bone disease (at least 1 bone lesion in breast cancer patients only)
  • For patients with an estrogen receptor (ER)+ breast cancer diagnosis:

    • If female, must be
    • If male, must agree to use hormone suppression
  • Phase 1a:

    -- Dose escalation and backfill patients:

    • Advanced solid tumor
    • Patients may have had up to 5 prior regimens for advanced disease
  • Phase 1b:

    • Part A:

      • ER+/human epidermal growth factor receptor 2 ()- advanced breast cancer
      • Patients may have had up to 5 prior regimens for advanced disease ---- Prior cyclin dependent kinase (CDK)4/6 inhibitor therapy required
    • Part B:

      • ER+/HER2- advanced breast cancer
      • Patients may have had up to 2 prior regimens for advanced disease.
    • Part C:

      • ER+/HER2- advanced breast cancer
      • Patients may have had up to 5 prior regimens for advanced disease.

        ---- Prior CDK4/6 inhibitor therapy required.

      • Have a diagnosis of diabetes mellitus Type 2
    • Part D:

      • Advanced breast cancer
      • Patients may have had up to 5 prior regimens for advanced disease.
    • Part E:

      • Advanced solid tumor
      • Patients may have had up to 3 prior regimens for advanced disease advanced disease
    • Part F:

      • ER+/HER2- advanced breast cancer
      • Patients may have had up to 5 prior regimens for advanced disease

        • Prior cyclin dependent kinase (CDK)4/6 inhibitor therapy required

Exclusion criteria

Exclusion Criteria:

  • Medical Conditions

    • Colorectal cancer
    • Endometrial cancers with specific concurrent oncogenic alterations
    • A history of known active or suspected

      • Diabetes mellitus Type 1 or
      • Diabetes mellitus Type 2 requiring antidiabetic medication (Phase 1a and all parts of Phase 1b except Part C).
      • Serious concomitant systemic disorder
  • Known or suspected history of untreated or uncontrolled central nervous system (CNS) involvement.
  • Active uncontrolled systemic bacterial, viral, fungal, or parasitic infection, or other active disease process
  • Prior exposure to phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) inhibitor(s), except in certain circumstances
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
260 participants (estimated)

Study arms

  • Experimental
    Phase 1A: LOXO-783 Monotherapy Dose Escalation

    LOXO-783 administered orally

    Drug: LOXO-783

  • Experimental
    Phase 1B: Part A

    LOXO-783 administered orally in combination with fulvestrant intramuscularly, imlunestrant orally, or an aromatase inhibitor orally

    Drug: LOXO-783 · Drug: Fulvestrant · Drug: Imlunestrant · Drug: Anastrozole, Exemestane, or Letrozole

  • Experimental
    Phase 1B: Part B

    LOXO-783 orally in combination with abemaciclib and either physician's choice aromatase inhibitor orally, fulvestrant intramuscularly, or imlunestrant orally

    Drug: LOXO-783 · Drug: Fulvestrant · Drug: Imlunestrant · Drug: Abemaciclib · Drug: Anastrozole, Exemestane, or Letrozole

  • Experimental
    Phase 1B: Part C

    LOXO-783 orally in combination with fulvestrant intramuscularly

    Drug: LOXO-783 · Drug: Fulvestrant

  • Experimental
    Phase 1B: Part D

    LOXO-783 orally in combination with paclitaxel intravenously

    Drug: LOXO-783 · Drug: Paclitaxel

  • Experimental
    Phase 1B: Part E

    LOXO-783 orally

    Drug: LOXO-783

  • Experimental
    Phase 1B: Part F

    Multiple randomized dose levels of LOXO-783 orally with fulvestrant intramuscularly

    Drug: LOXO-783 · Drug: Fulvestrant

Interventions

This study also gives AnastrozoleStudies of AnastrozoleAnastrozole pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., ExemestaneStudies of ExemestaneExemestane pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Phase 1 a: To determine the maximum tolerated dose/recommended phase 2 dose (MTD/RP2D) of LOXO-783: Number of patients with dose-limiting toxicities (DLTs)

    Number of patients with DLTs

    Time frame: During the first 28-day cycle of LOXO-783 treatment

  2. Phase 1 a: To determine the MTD/RP2D of LOXO-783: Number of patients with DLT-equivalent toxicities

    Number of patients with DLT-equivalent toxicities

    Time frame: During the first 28-day cycle of LOXO-783 treatment

Secondary outcomes

  1. To assess the pharmacokinetics (PK) of LOXO-783: Area under the concentration versus time curve (AUC)

    PK of LOXO-783: AUC

    Time frame: Up to 2 months

  2. To assess the PK of LOXO-783: Maximum drug concentration (Cmax)

    PK of LOXO-783: Cmax

    Time frame: Up to 2 months

  3. To evaluate the preliminary antitumor activity of LOXO-783: Overall response rate (ORR)

    ORR per investigator assessed Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1)

    Time frame: Up to approximately 36 months or 3 years

  4. To evaluate the preliminary antitumor activity of LOXO-783: Best overall response (BOR)

    BOR per investigator assessed RECIST 1.1

    Time frame: Up to approximately 36 months or 3 years

  5. To evaluate the preliminary antitumor activity of LOXO-783: Duration of response (DOR)

    DOR per investigator assessed RECIST 1.1

    Time frame: Up to approximately 36 months or 3 years

  6. To evaluate the preliminary antitumor activity of LOXO-783: Disease control rate (DCR)

    DCR per investigator assessed RECIST 1.1

    Time frame: Up to approximately 36 months or 3 years

  7. To evaluate the preliminary antitumor activity of LOXO-783: Clinical benefit rate (CBR)

    CBR per investigator assessed RECIST 1.1

    Time frame: Up to approximately 36 months or 3 years

  8. To evaluate the preliminary antitumor activity of LOXO-783: Time to response (TTR)

    TTR per investigator assessed RECIST 1.1

    Time frame: Up to approximately 36 months or 3 years

  9. To evaluate the preliminary antitumor activity of LOXO-783: Progression free survival (PFS)

    PFS per investigator assessed RECIST 1.1

    Time frame: Up to approximately 36 months or 3 years

  10. To evaluate the preliminary antitumor activity of LOXO-783: Overall survival (OS)

    OS per investigator assessed RECIST 1.1

    Time frame: Up to approximately 36 months or 3 years

07

Study locations

50 sites
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Apr 2025, 34 months.

Of 390 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's 34 months is below that.

Counting every sponsor, half of 763 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

Primary completion moved once since we started tracking on Sep 25, 2026: Dec 2026 → Apr 2025, on Oct 14, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2022
First posted
Apr 1, 2022
StartActual
May 11, 2022
Primary completionActual
Apr 2, 2025was Dec 2026
CompletionEst.
Dec 2026
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 14, 2026
Primary completion
Dec 2026→Apr 2, 2025 (actual)
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Recruiting→Active, not recruiting
    Primary completion Dec 2026→Apr 2, 2025 (now actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05307705
Responsible party
Sponsor
First posted
Apr 1, 2022
Start date
May 11, 2022
Primary completion
Apr 2, 2025
Completion
Dec 2026 (estimated)
Last update
Oct 14, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mutant-selective PI3K-alpha H1047R Inhibitor LOXO-783

Start the discussion